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Background:  Statins reduce cardiovascular events however limitations to therapy include poor long-term adherence, cost and adverse events. An 
alternative dosing strategy, such as a once weekly (Qwk) dose, may potentially limit these common barriers. We hypothesized a high-dose Qwk statin 
regimen would produce comparable lipid changes and safety measures as standard daily dosing.
Methods:  Participants were randomized to either rosuvastatin 80 mg Qwk (n=10) or atorvastatin 10 mg daily (n=7) in an 8 week double blind 
pilot study. Lipid profiles, hsCRP, hepatic panels and creatinine kinase were assessed at baseline, and 1-4 and 5-8 days after last dose.
Results:  Both treatments produced significant reductions (p<0.05) in total cholesterol and LDL-C from baseline to 1-4 and 5-8 days after last 
dose (table). No significant differences were noted between the two groups for changes in HDL-C, triglycerides and hsCRP. Each treatment was well 
tolerated with no serious adverse events. 
Conclusions:  Rosuvastatin 80mg Qwk provides comparable LDL-C reductions to atorvastatin 10mg daily. A high-dose Qwk statin regimen may be 
an alternative for patients with major barriers to standard daily therapy. 
Rosuvastatin 
80 mg Qwk
Atorvastatin 10mg Daily
P value
(between groups)
Baseline LDL-C (mg/dL) 148.5 + 28.6 142.3 + 38.1 0.710
Mean LDL-C reduction (%)
1-4 days post last dose* -33.7 ± 11.1 -36.0 ± 6.7 0.636
5-8 days post last dose** -25.0 ± 7.7 -26.8 ± 12.5 0.706
Overall -29.3 ± 6.7 -31.4 ± 8.3 0.575
* mean 2.23 ± 0.83 Days
** mean 5.94 ± 0.97 Days
